The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma
Abstract
Purpose: Anthracycline-based chemotherapy, which improves survival for patients with non-Hodgkin's lymphoma, is often withheld from elderly patients because of its cardiotoxicity. We studied the cardiac effects of doxorubicin in a population-based sample of older patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods: Among patients age ≥ 65 years diagnosed with DLBCL from 1991 to 2002 in the Surveillance, Epidemiology, and End Results–Medicare database, we developed logistic regression models of the associations of doxorubicin with demographic, clinical, and cardiac variables. We then developed Cox proportional hazards models of the association between doxorubicin and subsequent congestive heart failure (CHF), taking predictors of CHF into account. Results: Of 9,438 patients with DLBCL, 3,164 (42%) received doxorubicin-based chemotherapy. Any doxorubicin use was associated with a 29% increase in risk of CHF (95% CI, 1.02 to 1.62); CHF risk increased with number of doxorubicin claims, increasing age, prior heart disease, comorbidities, diabetes, and hypertension; hypertension intensified the effect of doxorubicin on risk of CHF (hazard ratio = 1.8; P < .01). In the 8 years after diagnosis, the adjusted CHF-free survival rate was 74% in doxorubicin-treated patients versus 79% in patients not treated with doxorubicin. Conclusion: Among patients receiving chemotherapy for DLBCL, those with prior heart disease were less likely than others to be treated with doxorubicin, and those who received doxorubicin were more likely than others to develop CHF. Various cardiac risk factors increased CHF risk, but only hypertension was synergistic with doxorubicin. Doxorubicin has dramatically improved survival of DLBCL patients; nonetheless, some subgroups may benefit from efforts to reduce doxorubicin-related CHF risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
He, J., Ogden, L. G., Bazzano, L. A., Vupputuri, S., Loria, C., & Whelton, P. K. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.7.996 · Cited by 1,172
Racial Differences in the Treatment of Early-Stage Lung Cancer
Bach, P. B., Cramer, L. D., Warren, J. L., & Begg, C. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411606 · Cited by 994
Adjusted survival curves with inverse probability weights
Cole, S. R., & Hernán, M. A. (2004) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2003.10.004 · Cited by 814
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
POTOSKY, A. L., RILEY, G. F., LUBITZ, J. D., MENTNECH, R. M., & KESSLER, L. G. (1993) · Medical Care · doi:10.1097/00005650-199308000-00006 · Cited by 694
Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4976 · Cited by 634
Utility of the SEER-Medicare Data to Identify Chemotherapy Use
Warren, J. L., Harlan, L. C., Fahey, A., Virnig, B. A., Freeman, J. L., Klabunde, C. N., Cooper, G. S., & Knopf, K. B. (2002) · Medical Care · doi:10.1097/00005650-200208001-00008 · Cited by 404
Missed Opportunities: Racial Disparities in Adjuvant Breast Cancer Treatment
Bickell, N. A., Wang, J. J., Oluwole, S., Schrag, D., Godfrey, H., Hiotis, K., Mendez, J., & Guth, A. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5799 · Cited by 363
Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
Hequet, O., Le, Q. H., Moullet, I., Pauli, E., Salles, G., Espinouse, D., Dumontet, C., Thieblemont, C., Arnaud, P., Antal, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.033 · Cited by 340
Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., & Hershman, D. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5841 · Cited by 335
Self-citationLyman, G. H., Dale, D. C., Friedberg, J., Crawford, J., & Fisher, R. I. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.213 · Cited by 315
Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer
Hershman, D., McBride, R., Jacobson, J. S., Lamerato, L., Roberts, K., Grann, V. R., & Neugut, A. I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.633 · Cited by 308
Self-citationSwain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
Schuchter, L. M., Hensley, M. L., Meropol, N. J., & Winer, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.178 · Cited by 262
Bach, P. B., Guadagnoli, E., Schrag, D., Schussler, N., & Warren, J. L. (2002) · Medical Care · doi:10.1097/00005650-200208001-00003 · Cited by 245
The Effect of Race on Invasive Staging and Surgery in Non–Small-Cell Lung Cancer
Lathan, C. S., Neville, B. A., & Earle, C. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1758 · Cited by 240
ARMITAGE, J. O., & POTTER, J. F. (1984) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1984.tb02020.x · Cited by 230
Krieger, N., Quesenberry, C., Peng, T., Horn-Ross, P., Stewart, S., Brown, S., Swallen, K., Guillermo, T., Suh, D., Alvarez-Martinez, L., et al. (1999) · Cancer Causes & Control · doi:10.1023/a:1008950210967 · Cited by 223
Silliman, R. A., Guadagnoli, E., Weitberg, A. B., & Mor, V. (1989) · Journal of Gerontology · doi:10.1093/geronj/44.2.m46 · Cited by 191
Explaining Black–White Differences in Receipt of Recommended Colon Cancer Treatment
Baldwin, L.-M., Dobie, S. A., Billingsley, K., Cai, Y., Wright, G. E., Dominitz, J. A., Barlow, W., Warren, J. L., & Taplin, S. H. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji241 · Cited by 187
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
Moser, E. C. (2006) · Blood · doi:10.1182/blood-2005-08-3392 · Cited by 174
Doorduijn, J. K., van der Holt, B., van Imhoff, G. W., van der Hem, K. G., Kramer, M. H. H., van Oers, M. H. J., Ossenkoppele, G. J., Schaafsma, M. R., Verdonck, L. F., Verhoef, G. E. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.076 · Cited by 168
Gómez, H., Mas, L., Casanova, L., Pen, D. L., Santillana, S., Valdivia, S., Otero, J., Rodriguez, W., Carracedo, C., & Vallejos, C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2352 · Cited by 155
Zinzani, P. L., Storti, S., Zaccaria, A., Moretti, L., Magagnoli, M., Pavone, E., Gentilini, P., Guardigni, L., Gobbi, M., Fattori, P. P., et al. (1999) · PubMed · Cited by 152
Doxorubicin-induced cardiomyopathy
(1984) · Reactions Weekly · doi:10.1007/bf03273255 · Cited by 139
Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin’s lymphoma
Limat, S., Demesmay, K., Voillat, L., Bernard, Y. F., Deconinck, É., Brion, A., Rebibo-Sabbah, A., Woronoff-Lemsi, M. C., & Cahn, J.-Y. Y. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg070 · Cited by 133
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer
Shavers, V. L., Brown, M. L., Potosky, A. L., Klabunde, C. N., Davis, W. W., Moul, J. W., & Fahey, A. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30209.x · Cited by 129
Jones, L. W., Haykowsky, M. J., Peddle‐McIntyre, C. J., Joy, A. A., Pituskin, E., Tkachuk, L., Courneya, K. S., Slamon, D. J., & Mackey, J. R. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0870 · Cited by 120
Heart Failure in African Americans
Yancy, C. W. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.028 · Cited by 108
Martelli, M., Guglielmi, C., Coluzzi, S., Avvisati, G., Amadori, S., Giovannini, M., Torromeo, C., & Mandelli, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.12.2362 · Cited by 75
Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer
Hershman, D. L., Jacobson, J. S., McBride, R. B., Mitra, N., Sundararajan, V., Grann, V. R., & Neugut, A. I. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.04.022 · Cited by 66
Self-citationConstruct Validity of Medicare Chemotherapy Claims: The Case of 5FU
Lamont, E. B., Lauderdale, D. S., Schilsky, R. L., & Christakis, N. A. (2002) · Medical Care · doi:10.1097/00005650-200203000-00004 · Cited by 53
Chrischilles, E. A., Link, B. K., Scott, S. D., Delgado, D. J., & Fridman, M. (2003) · Cancer Control · doi:10.1177/107327480301000507 · Cited by 53
Chen-Hardee, S., Chrischilles, E. A., Voelker, M. D., Brooks, J. M., Scott, S., Link, B. K., & Delgado, D. (2006) · Cancer Causes & Control · doi:10.1007/s10552-005-0502-4 · Cited by 52
Kouroukis, C. T., Browman, G. P., Esmail, R., & Meyer, R. M. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-2-200201150-00012 · Cited by 46
Grann, V. R., Hershman, D. L., Jacobson, J. S., Tsai, W., Wang, J., McBride, R. B., Mitra, N., Grossbard, M. L., & Neugut, A. I. (2006) · Cancer · doi:10.1002/cncr.22188 · Cited by 40
Self-citationColon Cancer Treatment in Rural North and South Carolina
Hawley, S. T., Hatzell, T. A., Paskett, E. D., Ricketts, T. C., Cooper, M. R., & Aldrich, T. E. (1999) · Cancer Detection and Prevention · doi:10.1046/j.1525-1500.1999.99042.x · Cited by 36
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Metadata
- Authors
- Hershman, D. L., McBride, R. B., Eisenberger, A., Tsai, W. Y., Grann, V. R., & Jacobson, J. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-01
- Volume
- 26
- Issue
- 19
- Pages
- 3159-3165
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2152124377
- Cited by
- 390
- References
- 41
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.